$39.5 Million Secured To Advance Small Molecule Correctors Into Clinical Development
Congruence Therapeutics has announced the closing of a $39.5 million financing to support the advancement of its pipeline of small molecule correctors targeting diseases caused by protein misfolding. The financing round was co-led by Dimension and OrbiMed, with participation from Amplitude Ventures, FSTQ, Lumira Ventures, Investissement Québec, BDC Capital, Driehaus Capital Management, and Silver Arc. … Read more